(Q43631091)

25 November 2017

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam (English)

1 reference

25 November 2017

1 reference

René Raaijmakers

1

1 reference

25 November 2017

Mark F Wildhagen

2

1 reference

25 November 2017

Kazuto Ito

3

1 reference

25 November 2017

Alvaro Pàez

4

1 reference

25 November 2017

Stijn H de Vries

5

1 reference

25 November 2017

Monique J Roobol

6

1 reference

25 November 2017

Fritz H Schröder

7

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

25 November 2017

1 reference

25 November 2017

63

1 reference

25 November 2017

316-320

1 reference

25 November 2017

2

1 reference

European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies.

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Different PSA Assays Lead to Detection of Prostate Cancers with Identical Histological Features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Screening for prostatic carcinoma with prostate specific antigen: results of the second year.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

PSA doubling time of prostate carcinoma managed with watchful observation alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.028

10.1016/J.UROLOGY.2003.09.028

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference